유전자 치료 시장(2026-2030년)

The global gene therapy market is forecasted to grow by USD 10667.9 mn during 2025-2030, accelerating at a CAGR of 25.0% during the forecast period. The report on the global gene therapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global burden of genetic abnormalities and oncological malignancies, technological advancements in vector delivery and gene editing platforms, regulatory support and streamlined approval pathways.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global gene therapy market is segmented as below:

By Delivery Mode

• In vivo
• Ex vivo

By Therapy Area

• Oncology
• CNS
• Rare diseases
• Ophthalmology
• Others

By End-User

• Hospitals
• Specialty clinics
• Academic and research institutes

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the shift toward non-viral delivery systems and nanotechnology platforms as one of the prime reasons driving the global gene therapy market growth during the next few years. Also, increasing integration of ai in computational vector engineering and proactive evolution toward allogeneic cellular formulations will lead to sizable demand in the market.

The report on the global gene therapy market covers the following areas:

• Global gene therapy market sizing
• Global gene therapy market forecast
• Global gene therapy market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global gene therapy market vendors that include Amgen Inc., Autolus Therapeutics plc, BioMarin Pharmaceutical Inc., Bristol Myers Squibb Co., CRISPR Therapeutics AG, CSL Behring, Dendreon Pharmaceuticals LLC, F. Hoffmann La Roche Ltd., Ferring BV, Fondazione Telethon, Genetix Biotherapeutics Inc., Gilead Sciences Inc., IOVANCE Biotherapeutics Inc., Johnson and Johnson, Krystal Biotech Inc., Kyowa Kirin Co. Ltd., Neurotech Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Precigen Inc., PTC Therapeutics Inc., Sarepta Therapeutics Inc., USWM LLC, Vertex Pharmaceuticals Inc.. Also, the global gene therapy market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Delivery Mode
  • Executive Summary - Chart on Market Segmentation by Therapy Area
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Gene Therapy Market 2020 - 2024
  • Historic Market Size - Data Table on Global Gene Therapy Market 2020 - 2024 ($ million)
• 5.2 Delivery Mode segment analysis 2020 - 2024
  • Historic Market Size - Delivery Mode Segment 2020 - 2024 ($ million)
• 5.3 Therapy Area segment analysis 2020 - 2024
  • Historic Market Size - Therapy Area Segment 2020 - 2024 ($ million)
• 5.4 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global gene therapy market
• 6.2 Impact of geopolitical conflicts on global gene therapy market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Delivery Mode

• 8.1 Market segments
• 8.2 Comparison by Delivery Mode
• 8.3 In vivo - Market size and forecast 2025-2030
• 8.4 Ex vivo - Market size and forecast 2025-2030
• 8.5 Market opportunity by Delivery Mode
  • Market opportunity by Delivery Mode ($ million)

9 Market Segmentation by Therapy Area

• 9.1 Market segments
• 9.2 Comparison by Therapy Area
• 9.3 Oncology - Market size and forecast 2025-2030
• 9.4 CNS - Market size and forecast 2025-2030
• 9.5 Rare diseases - Market size and forecast 2025-2030
• 9.6 Ophthalmology - Market size and forecast 2025-2030
• 9.7 Others - Market size and forecast 2025-2030
• 9.8 Market opportunity by Therapy Area
  • Market opportunity by Therapy Area ($ million)

10 Market Segmentation by End-user

• 10.1 Market segments
• 10.2 Comparison by End-user
• 10.3 Hospitals - Market size and forecast 2025-2030
• 10.4 Specialty clinics - Market size and forecast 2025-2030
• 10.5 Academic and research institutes - Market size and forecast 2025-2030
• 10.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 India - Market size and forecast 2025-2030
  • 12.5.3 Japan - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 Colombia - Market size and forecast 2025-2030
  • 12.6.7 South Africa - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Rising global burden of genetic abnormalities and oncological malignancies
  • Technological advancements in vector delivery and gene editing platforms
  • Regulatory support and streamlined approval pathways
• 13.2 Market challenges
  • High costs and complex reimbursement frameworks
  • Severe manufacturing bottlenecks and scalability constraints
  • Persistent safety risks and long-term durability uncertainties
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Shift toward non-viral delivery systems and nanotechnology platforms
  • Increasing integration of AI in computational vector engineering
  • Proactive evolution toward allogeneic cellular formulations

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Amgen Inc.
  • Amgen Inc. - Overview
  • Amgen Inc. - Product / Service
  • Amgen Inc. - Key news
  • Amgen Inc. - Key offerings
  • SWOT
• 15.5 Autolus Therapeutics plc
  • Autolus Therapeutics plc - Overview
  • Autolus Therapeutics plc - Product / Service
  • Autolus Therapeutics plc - Key offerings
  • SWOT
• 15.6 BioMarin Pharmaceutical Inc.
  • BioMarin Pharmaceutical Inc. - Overview
  • BioMarin Pharmaceutical Inc. - Business segments
  • BioMarin Pharmaceutical Inc. - Key offerings
  • BioMarin Pharmaceutical Inc. - Segment focus
  • SWOT
• 15.7 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT
• 15.8 CSL Behring
  • CSL Behring - Overview
  • CSL Behring - Product / Service
  • CSL Behring - Key offerings
  • SWOT
• 15.9 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.10 Ferring BV
  • Ferring BV - Overview
  • Ferring BV - Product / Service
  • Ferring BV - Key offerings
  • SWOT
• 15.11 Fondazione Telethon
  • Fondazione Telethon - Overview
  • Fondazione Telethon - Product / Service
  • Fondazione Telethon - Key offerings
  • SWOT
• 15.12 Gilead Sciences Inc.
  • Gilead Sciences Inc. - Overview
  • Gilead Sciences Inc. - Business segments
  • Gilead Sciences Inc. - Key news
  • Gilead Sciences Inc. - Key offerings
  • Gilead Sciences Inc. - Segment focus
  • SWOT
• 15.13 Johnson and Johnson
  • Johnson and Johnson - Overview
  • Johnson and Johnson - Business segments
  • Johnson and Johnson - Key news
  • Johnson and Johnson - Key offerings
  • Johnson and Johnson - Segment focus
  • SWOT
• 15.14 Kyowa Kirin Co. Ltd.
  • Kyowa Kirin Co. Ltd. - Overview
  • Kyowa Kirin Co. Ltd. - Business segments
  • Kyowa Kirin Co. Ltd. - Key offerings
  • Kyowa Kirin Co. Ltd. - Segment focus
  • SWOT
• 15.15 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.16 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.17 USWM LLC
  • USWM LLC - Overview
  • USWM LLC - Product / Service
  • USWM LLC - Key offerings
  • SWOT
• 15.18 Vertex Pharmaceuticals Inc.
  • Vertex Pharmaceuticals Inc. - Overview
  • Vertex Pharmaceuticals Inc. - Product / Service
  • Vertex Pharmaceuticals Inc. - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations